Monday, 14 August 2017

Biogerontology Research Foundation salutes staff on multi-year drug development agreement

(Biogerontology Research Foundation) Biogerontology Research Foundation (BGRF) Chief Science Officer Alex Zhavoronkov and BGRF Trustee Jim Mellon announce a multi-year drug development agreement, whereby Juvenescence Limited (led by Jim Mellon) will utilize leads generated by Insilico Medicine (led by Dr. Zhavoronkov) through their deep-learned drug discovery engines to develop drugs aiming to treat aging and age-related diseases, as well as a set of companion multi-modal age-related disease biomarkers.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2hZ7YM5

No comments:

Post a Comment